Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases. The company has a collaboration agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101; and Adaptimmune Therapeutics plc to develop next-generation SPEAR T cell products. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.
Alpine Immune Sciences, Inc. (ALPN) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2023 | 749 K | -34,007,000 | 51.91 M | 379.85 M | 330.03 M |
| 2022 | 709 K | 845 K | 107.27 M | 286.69 M | 240.99 M |
| 2021 | 25.32 M | -48,279,000 | 135 M | 255.9 M | 192.01 M |
| 2020 | 388 K | -12,361,000 | 81.93 M | 144.09 M | 107.1 M |
| 2019 | 686 K | 233 K | 24.62 M | 54.09 M | 42.3 M |